Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|5|694-703

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.5, 2014-02, pp. : 694-703

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prospects for the Resistance to HIV Protease Inhibitors: Current Drug Design Approaches and Perspectives

By  

Current Pharmaceutical Design, Vol. 11, Iss. 24, 2005-01 ,pp. : 3077-3090

Bentham Science Publishers

Access to resources Recommend Favorite

HCV NS2/3 protease: a future antiviral drug target?

By Welbourn Sarah   Pause Arnim  

Future Virology, Vol. 4, Iss. 5, 2009-09 ,pp. : 463-472

Future Medicine

Access to resources Recommend Favorite

Macrocyclic Inhibitors of HCV NS3-4A Protease: Design and Structure Activity Relationship

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 13, 2007-07 ,pp. : 1290-1301

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery of Small-Molecule Inhibitors of HCV NS3-4A Protease as Potential Therapeutic Agents against HCV Infection

By  

Current Medicinal Chemistry, Vol. 12, Iss. 20, 2005-09 ,pp. : 2317-2342

Bentham Science Publishers

Access to resources Recommend Favorite

Resistance of HBV and HCV to antiviral therapies

By Polyak Stephen J  

Future Virology, Vol. 3, Iss. 3, 2008-05 ,pp. : 221-224

Future Medicine

Access to resources Recommend Favorite